First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models Highlights First-in-class TRH-based compound JAK4D detects new receptor subtype in human brain. JAK4D elicits statistically significant effects in neurodegenerative animal models. JAK4D crosses the blood–brain barrier and has a clean initial toxicology profile.… Read More

Maybe neuroscience needs ‘malbrain’ to complement cell biology’s ‘cancer’ in the public mind…***

Previously, I wondered why there was no hue-and-cry over the huge disinvestment in brain research over the past decade, and why, by comparison, cancer research does well.* ‘Cancer‘ is understood by the public at large, by the political establishment, by the pharmaceutical companies and a host of other stakeholders as a single-word issue of great and pressing concern to… Read More